share_log

Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Benzinga ·  Aug 30, 2023 04:09

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $415 to $440.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment